Canada has an opportunity to prevent sustained Clade I mpox transmission, but only if decisive action is taken now.
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback